This page has only limited features, please log in for full access.

Prof. Giovanni Sotgiu
University of Sassari

Basic Info


Research Keywords & Expertise

0 Epidemiology
0 Infectious Diseases
0 Tuberculosis
0 statistical analysis
0 Epidemiology of infectious diseases

Fingerprints

Tuberculosis
Epidemiology
Infectious Diseases

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 14 August 2021 in International Journal of Molecular Sciences
Reads 0
Downloads 0

EGFR is overexpressed in the majority of clear cell renal cell carcinomas (CCRCCs). Although EGFR deregulation was found to be of great significance in CCRCC biology, the EGFR overexpression is not associated with EGFR-targeted therapy responsiveness. Moreover, the prognostic role of EGFR expression remains controversial. In the present study, we evaluated the role played by EGFR overexpression in CCRCC and its prognostic significance associated with different immunohistochemical localization patterns. In our study, the Total Score (TS) related to membranous-cytoplasmic EGFR expression showed a significant correlation with grade, pathologic stage (pT), and Stage, Size, Grade, and Necrosis (SSIGN) score, and a negative correlation with nuclear EGFR expression. No significant correlations were shown between nuclear EGFR and clinic-pathological features. Additionally, a correlation between SGLT1 expression levels and pT was described. Multivariate analysis identifies pT and SSIGN score as independent prognostic factors for CCRCC. A significantly increased survival rate was found in the case of positive expression of nuclear EGFR and SGLT1. Based on our findings, SGLT1 and nuclear EGFR overexpression defines a subgroup of CCRCC patients with good prognosis. Membranous-cytoplasmic EGFR expression was shown to be a poor prognostic factor and could define a CCRCC subgroup with poor prognosis that should be responsive to anti-EGFR therapies.

ACS Style

Maria Rosaria Muroni; Silvia Ribback; Giovanni Sotgiu; Nils Kroeger; Laura Saderi; Andrea Angius; Paolo Cossu-Rocca; Maria Rosaria De Miglio. Prognostic Impact of Membranous/Nuclear Epidermal Growth Factor Receptor Localization in Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences 2021, 22, 8747 .

AMA Style

Maria Rosaria Muroni, Silvia Ribback, Giovanni Sotgiu, Nils Kroeger, Laura Saderi, Andrea Angius, Paolo Cossu-Rocca, Maria Rosaria De Miglio. Prognostic Impact of Membranous/Nuclear Epidermal Growth Factor Receptor Localization in Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences. 2021; 22 (16):8747.

Chicago/Turabian Style

Maria Rosaria Muroni; Silvia Ribback; Giovanni Sotgiu; Nils Kroeger; Laura Saderi; Andrea Angius; Paolo Cossu-Rocca; Maria Rosaria De Miglio. 2021. "Prognostic Impact of Membranous/Nuclear Epidermal Growth Factor Receptor Localization in Clear Cell Renal Cell Carcinoma." International Journal of Molecular Sciences 22, no. 16: 8747.

Chapter
Published: 27 July 2021 in Essential Tuberculosis
Reads 0
Downloads 0

This chapter summarizes briefly the history of anti-tuberculosis (TB) chemotherapy and discusses its principles, the different populations of Mycobacterium tuberculosis bacilli, and the probability they have to develop resistance to the anti-TB drugs. The bactericidal and sterilizing activity of the available anti-TB drugs is also presented, to define the minimum requirements for an anti-TB regimen and to shed light on the possible future of anti-TB regimens. In the future of anti-TB regimens we see the possibility, on one side to use new drugs which are presently in the development pipeline, and on the other side to better understand how to use new and repurposed drugs within effective and well-tolerated regimens.

ACS Style

José Caminero Luna; Giovanni Battista Migliori. Rationale for Anti-Tuberculosis Chemotherapy. Essential Tuberculosis 2021, 109 -120.

AMA Style

José Caminero Luna, Giovanni Battista Migliori. Rationale for Anti-Tuberculosis Chemotherapy. Essential Tuberculosis. 2021; ():109-120.

Chicago/Turabian Style

José Caminero Luna; Giovanni Battista Migliori. 2021. "Rationale for Anti-Tuberculosis Chemotherapy." Essential Tuberculosis , no. : 109-120.

Chapter
Published: 27 July 2021 in Essential Tuberculosis
Reads 0
Downloads 0

The annual incidence of tuberculosis (TB) cases and the prevalence of individuals with tuberculosis infection can decrease reducing the Mycobacterium tuberculosis transmission. Early diagnosis and immediate prescription of effective therapy are key elements of a successful public health strategy. The TB epidemiology in low-TB incidence settings can be influenced by the occurrence of outbreaks in the community or in congregate settings. In general, an outbreak is a public health emergency, which needs a rapid intervention. Identification of the source and/or the index case is key to detect all exposed individuals who can potentially have been infected. A coordinated response, based on a comprehensive action plan, could assess the chain of transmission and avoid future cases of disease perpetuating transmission of infection.

ACS Style

Giovanni Sotgiu. Managing Tuberculosis Outbreaks in Low-Incidence Settings. Essential Tuberculosis 2021, 331 -338.

AMA Style

Giovanni Sotgiu. Managing Tuberculosis Outbreaks in Low-Incidence Settings. Essential Tuberculosis. 2021; ():331-338.

Chicago/Turabian Style

Giovanni Sotgiu. 2021. "Managing Tuberculosis Outbreaks in Low-Incidence Settings." Essential Tuberculosis , no. : 331-338.

Chapter
Published: 27 July 2021 in Essential Tuberculosis
Reads 0
Downloads 0

The present debate on multidrug-resistant tuberculosis (TB), and the evidence from existing hotspots, suggest that priority actions are necessary to prevent transmission, particularly in hospitals and other health care facilities as well as in congregate settings. This chapter describes the traditional infection control pillars (administrative, environmental controls and personal respiratory protection measures) and discusses the approaches to limit transmission. In particular, it describes the FAST (Find cases Actively by cough surveillance and rapid molecular sputum testing, Separate safely and Treat effectively based on rapid drug susceptibility testing) approach, and the importance to reduce unnecessary hospitalization. Based on recent evidence guidance is provided as to define the need and requirement for hospital admission and discharge. The chapter includes a ‘questions and answers’ section taking advantages from a recent consensus document of experts published by the WHO European Region. Furthermore, the chapter proposes an exercise for self-learning.

ACS Style

Giovanni Battista Migliori; Grigory Volchenkov. Tuberculosis Infection Control. Essential Tuberculosis 2021, 67 -76.

AMA Style

Giovanni Battista Migliori, Grigory Volchenkov. Tuberculosis Infection Control. Essential Tuberculosis. 2021; ():67-76.

Chicago/Turabian Style

Giovanni Battista Migliori; Grigory Volchenkov. 2021. "Tuberculosis Infection Control." Essential Tuberculosis , no. : 67-76.

Chapter
Published: 27 July 2021 in Essential Tuberculosis
Reads 0
Downloads 0

Adequate national strategic planning (NSP) is an essential procedure to ensure that national tuberculosis programme’s (NTP) interventions are prioritized, costed and effectively implemented in order to reach the overall aim of their national strategy established to control and eventually eliminate tuberculosis (TB). NSP is a working tool for NTP staff, partners and stakeholders involved in TB control. This chapter is designed to provide guidance on the methodology to develop a NSP for TB care and control. It describes the process to design and prepare the NSP, identifying and outlining the key NSP components and providing instructions on how to build each of them. Furthermore, the chapter guides in developing a rational framework to describe the TB control situation, and to formulate goals, objectives, strategic interventions as well as activities and sub-activities related to each intervention. A sound NSP includes a core plan, a detailed budget plan, the monitoring and evaluation plan, the operational plan and the technical assistance plan. In challenging operating environments, an emergency preparedness plan will be also useful. Furthermore, the chapter proposes an exercise for self-learning.

ACS Style

Giovanni Battista Migliori; Giuliano Gargioni; Clarisse Veylon Hervet. National Tuberculosis Strategic Planning. Essential Tuberculosis 2021, 307 -318.

AMA Style

Giovanni Battista Migliori, Giuliano Gargioni, Clarisse Veylon Hervet. National Tuberculosis Strategic Planning. Essential Tuberculosis. 2021; ():307-318.

Chicago/Turabian Style

Giovanni Battista Migliori; Giuliano Gargioni; Clarisse Veylon Hervet. 2021. "National Tuberculosis Strategic Planning." Essential Tuberculosis , no. : 307-318.

Chapter
Published: 27 July 2021 in Essential Tuberculosis
Reads 0
Downloads 0

A new comorbidity of tuberculosis (TB) and COVID-19, caused by the Coronavirus SARS-CoV-2, has emerged rapidly during the year 2020. The implications of this twenty-first-century ‘cursed duet’ are of great concern for TB care and control efforts. Although current evidence remains limited, some observations are possible. For instance, COVID-19 does not seem to have a major impact on the clinical course of most TB patients. However, COVID-19 case fatality may be increased among patients with TB, older age and comorbidities may act as confounders. TB prevalence has been found to be higher among severe COVID-19 cases than among non-severe cases. Whether COVID-19 can accelerate the transition of TB infection towards disease remains unclear. No doubts, however, exist regarding the devastating impact of the COVID-19 pandemic on TB services and control activities. Reports from many countries emphasize reassignment of resources towards the crisis response and consequent disruptions of TB care services resulting in a significant reduction of TB case detection and an expected increase in unfavourable TB treatment outcomes including increased mortality. At the same time, initial experiences in some high-burden countries show that opportunities exist to exploit the assertive response to the pandemic to strengthen TB prevention, care and control in the future.

ACS Style

Giovanni Battista Migliori; Mario C. Raviglione. Tuberculosis and COVID-19 Comorbidity: A New Twenty-First-Century Cursed Duet. Essential Tuberculosis 2021, 221 -227.

AMA Style

Giovanni Battista Migliori, Mario C. Raviglione. Tuberculosis and COVID-19 Comorbidity: A New Twenty-First-Century Cursed Duet. Essential Tuberculosis. 2021; ():221-227.

Chicago/Turabian Style

Giovanni Battista Migliori; Mario C. Raviglione. 2021. "Tuberculosis and COVID-19 Comorbidity: A New Twenty-First-Century Cursed Duet." Essential Tuberculosis , no. : 221-227.

Journal article
Published: 02 July 2021 in Biomedicines
Reads 0
Downloads 0

Although bronchiectasis pathophysiology has been historically understood around the presence of airway neutrophilic inflammation, recent experiences are consistent with the identification of a type 2 inflammation (T2) high endotype in bronchiectasis. In order to evaluate prevalence and clinical characteristics of bronchiectasis patients with a T2-high endotype and explore their response to biologicals, two studies were carried out. In a cross-sectional study, bronchiectasis adults without asthma underwent clinical, radiological, and microbiological assessment, along with blood eosinophils and oral fractional exhaled nitric oxide (FeNO) evaluation, during stable state. Prevalence and characteristics of patients with a T2- high endotype (defined by the presence of either eosinophils blood count ≥300 cells·µL−1 or oral FeNO ≥ 25 dpp) were reported. A case series of severe asthmatic patients with concomitant bronchiectasis treated with either mepolizumab or benralizumab was evaluated, and patients’ clinical data pre- and post-treatment were analyzed up to 2 years of follow up. Among bronchiectasis patients without asthma enrolled in the cross-sectional study, a T2-high endotype was present in 31% of them. These patients exhibited a more severe disease, high dyspnea severity, low respiratory function, and high impact on quality of life. Among the five patients with severe eosinophilic asthma and concomitant bronchiectasis included in the series, treatment with either mepolizumab or benralizumab significantly reduced the exacerbation rate with an effect that persists for up to 2 years of follow up. If validated across different settings, our data suggest the need to design randomized controlled trials on biological treatments targeting the T2-high endotype in bronchiectasis patients.

ACS Style

Martina Oriano; Andrea Gramegna; Francesco Amati; Alice D’Adda; Michele Gaffuri; Marco Contoli; Francesco Bindo; Edoardo Simonetta; Carlotta Di Francesco; Martina Santambrogio; Giovanni Sotgiu; Francesco Blasi; Stefano Aliberti. T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis. Biomedicines 2021, 9, 772 .

AMA Style

Martina Oriano, Andrea Gramegna, Francesco Amati, Alice D’Adda, Michele Gaffuri, Marco Contoli, Francesco Bindo, Edoardo Simonetta, Carlotta Di Francesco, Martina Santambrogio, Giovanni Sotgiu, Francesco Blasi, Stefano Aliberti. T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis. Biomedicines. 2021; 9 (7):772.

Chicago/Turabian Style

Martina Oriano; Andrea Gramegna; Francesco Amati; Alice D’Adda; Michele Gaffuri; Marco Contoli; Francesco Bindo; Edoardo Simonetta; Carlotta Di Francesco; Martina Santambrogio; Giovanni Sotgiu; Francesco Blasi; Stefano Aliberti. 2021. "T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis." Biomedicines 9, no. 7: 772.

Review article
Published: 26 June 2021 in Current Opinion in Pharmacology
Reads 0
Downloads 0

The management of multidrug-resistant tuberculosis (TB) is associated with low treatment success, high mortality and failure rates. New drugs and novel short-therapeutic regimens have only recently helped overcome these obstacles. We carried out a narrative literature review aimed at summarizing the scientific evidence on the recent therapeutic advances in the field of drug-resistant TB. Experimental and observational studies on novel (i.e. bedaquiline, delamanid, pretomanid) drugs and novel regimens and the main pharmacological characteristics of the newest compounds are described. We also highlight the main scientific evidence on therapeutic strategies complementary to standard chemotherapy (i.e. new approaches to drug delivery, host-directed therapy, surgery, new collapse therapy, rehabilitation, and palliative care).

ACS Style

Michele Mondoni; Laura Saderi; Giovanni Sotgiu. Novel treatments in multidrug-resistant tuberculosis. Current Opinion in Pharmacology 2021, 59, 103 -115.

AMA Style

Michele Mondoni, Laura Saderi, Giovanni Sotgiu. Novel treatments in multidrug-resistant tuberculosis. Current Opinion in Pharmacology. 2021; 59 ():103-115.

Chicago/Turabian Style

Michele Mondoni; Laura Saderi; Giovanni Sotgiu. 2021. "Novel treatments in multidrug-resistant tuberculosis." Current Opinion in Pharmacology 59, no. : 103-115.

Journal article
Published: 11 June 2021 in ERJ Open Research
Reads 0
Downloads 0

An interventional pulmonary programme can be carried out safely for both cancer patients and HCWs during the #COVID19 pandemic. However, a worrisome reduction of new cancer patient referral occurs during periods of high community spread of the virus.https://bit.ly/2PRWNXo

ACS Style

Rocco Trisolini; Daniele Magnini; Vanina Livi; Fausto Leoncini; Lucia M. Porro; Maria C. Flore; Daniela Paioli; Giovanni Sotgiu. Pattern of cancer patients referral and organisational model of an interventional pulmonology programme during the COVID-19 pandemic. ERJ Open Research 2021, 7, 1 .

AMA Style

Rocco Trisolini, Daniele Magnini, Vanina Livi, Fausto Leoncini, Lucia M. Porro, Maria C. Flore, Daniela Paioli, Giovanni Sotgiu. Pattern of cancer patients referral and organisational model of an interventional pulmonology programme during the COVID-19 pandemic. ERJ Open Research. 2021; 7 (2):1.

Chicago/Turabian Style

Rocco Trisolini; Daniele Magnini; Vanina Livi; Fausto Leoncini; Lucia M. Porro; Maria C. Flore; Daniela Paioli; Giovanni Sotgiu. 2021. "Pattern of cancer patients referral and organisational model of an interventional pulmonology programme during the COVID-19 pandemic." ERJ Open Research 7, no. 2: 1.

Journal article
Published: 19 May 2021 in Journal of Clinical Medicine
Reads 0
Downloads 0

A multicenter, nonrandomized, prospective, controlled study was conducted to evaluate, as perioperative prophylactic treatment, the anti-infective effectiveness of 0.66% povidone-iodine eye drops (IODIM®) against the bacterial flora of the conjunctival surface of patients who undergo cataract surgery. Eye drops containing 0.66% povidone-iodine were applied to the eye undergoing cataract surgery; the untreated contralateral eye was used as control. One hundred and twenty patients set to receive unilateral cataract surgery were enrolled in 5 Italian Ophthalmology Centers and pretreated for three days with 0.66% povidone-iodine eye drops. The contralateral eye, used as control, was left untreated. Conjunctival swabs of both eyes were collected at the baseline visit and after three days of treatment, just before the cataract surgery. A qualitative and quantitative microbiological analysis of bacterial presence was evaluated by means of bacterial culture, followed by identification. Methicillin resistance determination was also performed on staphylococci isolates. Bacterial load before and after treatment of the eye candidate for cataract surgery was evaluated and compared to the untreated eye. A reduction or no regrowth on the culture media of the bacterial load was observed in 100% of the study subjects. A great heterogenicity of bacterial species was found. The 0.66% povidone-iodine eye drops, used for three days prior to cataract surgery, were effective in reducing the conjunctival bacterial load. The 0.66% povidone-iodine eye drops (IODIM®) might represent a valid perioperative prophylactic antiseptic adjuvant treatment to protect the ocular surface from microbial contamination in preparation of the surgical procedure.

ACS Style

Rosario Musumeci; Pasquale Troiano; Marianna Martinelli; Matteo Piovella; Claudio Carbonara; Scipione Rossi; Giovanni Alessio; Luisa Molteni; Claudio Molteni; Laura Saderi; Giovanni Sotgiu; Clementina Cocuzza. Effectiveness of 0.66% Povidone-Iodine Eye Drops on Ocular Surface Flora before Cataract Surgery: A Nationwide Microbiological Study. Journal of Clinical Medicine 2021, 10, 2198 .

AMA Style

Rosario Musumeci, Pasquale Troiano, Marianna Martinelli, Matteo Piovella, Claudio Carbonara, Scipione Rossi, Giovanni Alessio, Luisa Molteni, Claudio Molteni, Laura Saderi, Giovanni Sotgiu, Clementina Cocuzza. Effectiveness of 0.66% Povidone-Iodine Eye Drops on Ocular Surface Flora before Cataract Surgery: A Nationwide Microbiological Study. Journal of Clinical Medicine. 2021; 10 (10):2198.

Chicago/Turabian Style

Rosario Musumeci; Pasquale Troiano; Marianna Martinelli; Matteo Piovella; Claudio Carbonara; Scipione Rossi; Giovanni Alessio; Luisa Molteni; Claudio Molteni; Laura Saderi; Giovanni Sotgiu; Clementina Cocuzza. 2021. "Effectiveness of 0.66% Povidone-Iodine Eye Drops on Ocular Surface Flora before Cataract Surgery: A Nationwide Microbiological Study." Journal of Clinical Medicine 10, no. 10: 2198.

Journal article
Published: 29 April 2021 in European Respiratory Journal
Reads 0
Downloads 0
ACS Style

Rocco Francesco Rinaldo; Michele Mondoni; Elena Maria Parazzini; Federica Pitari; Elena Brambilla; Simone Luraschi; Maurizio Balbi; Giuseppe Francesco Sferrazza Papa; Giovanni Sotgiu; Marco Guazzi; Fabiano Di Marco; Stefano Centanni. Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors. European Respiratory Journal 2021, 58, 2100870 .

AMA Style

Rocco Francesco Rinaldo, Michele Mondoni, Elena Maria Parazzini, Federica Pitari, Elena Brambilla, Simone Luraschi, Maurizio Balbi, Giuseppe Francesco Sferrazza Papa, Giovanni Sotgiu, Marco Guazzi, Fabiano Di Marco, Stefano Centanni. Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors. European Respiratory Journal. 2021; 58 (2):2100870.

Chicago/Turabian Style

Rocco Francesco Rinaldo; Michele Mondoni; Elena Maria Parazzini; Federica Pitari; Elena Brambilla; Simone Luraschi; Maurizio Balbi; Giuseppe Francesco Sferrazza Papa; Giovanni Sotgiu; Marco Guazzi; Fabiano Di Marco; Stefano Centanni. 2021. "Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors." European Respiratory Journal 58, no. 2: 2100870.

Journal article
Published: 01 April 2021 in Future Microbiology
Reads 0
Downloads 0

Background: Tuberculosis (TB) unevenly affects individuals across the globe, especially in rural areas of low-income countries. Aim of the study was to assess the impact of social protection to increase TB awareness on treatment outcomes among TB patients in a rural area of Senegal. Materials & methods: The study, conducted in Fimela district (Senegal) from 1 January 2010 to 31 December 2019 and the intervention started from 31 January 2013, includes activities to increase awareness, active case finding, active follow-up and social protection. Results: Overall, 435 subjects – mainly male and young – were included in the analysis. Among TB cases, 94% had pulmonary involvement, 87% had no previous TB history, and 6% resulted positive HIV. Improved outcome was observed once intervention began (from 71 to 91%, p < 0.001); whereas mortality decreased (from 15 to 5%; p < 0.001), especially for those HIV co-infected for whom TB mortality rate dropped from 70 to 29%. Conclusion: After beginning the cooperation program, TB treatment success increased as a result of the decline of mortality, especially in people living with HIV.

ACS Style

Niccolò Riccardi; Simone Villa; Andrea Giacomelli; Mama M Diaw; Mamoud Ndiaye; Lamine Gning; Marta Robbiano; Riccardo Alagna; Laura Saderi; Antonio Di Biagio; Matteo Bassetti; Daniela M Cirillo; Giovanni Sotgiu; Luigi R Codecasa; Marie Sarr; Giorgio Besozzi. Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia. Future Microbiology 2021, 16, 399 -407.

AMA Style

Niccolò Riccardi, Simone Villa, Andrea Giacomelli, Mama M Diaw, Mamoud Ndiaye, Lamine Gning, Marta Robbiano, Riccardo Alagna, Laura Saderi, Antonio Di Biagio, Matteo Bassetti, Daniela M Cirillo, Giovanni Sotgiu, Luigi R Codecasa, Marie Sarr, Giorgio Besozzi. Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia. Future Microbiology. 2021; 16 (6):399-407.

Chicago/Turabian Style

Niccolò Riccardi; Simone Villa; Andrea Giacomelli; Mama M Diaw; Mamoud Ndiaye; Lamine Gning; Marta Robbiano; Riccardo Alagna; Laura Saderi; Antonio Di Biagio; Matteo Bassetti; Daniela M Cirillo; Giovanni Sotgiu; Luigi R Codecasa; Marie Sarr; Giorgio Besozzi. 2021. "Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia." Future Microbiology 16, no. 6: 399-407.

Journal article
Published: 09 March 2021 in Metabolites
Reads 0
Downloads 0

Prematurity is the leading cause of neonatal deaths and high economic costs; it depends on numerous biological and social factors, and is highly prevalent in males. Several factors can affect the metabolome of premature infants. Accordingly, the aim of the present study was to analyze the role played by gestational age (GA), parenteral nutrition (PN), and caffeine treatment in sex-related differences of blood metabolome of premature neonates through a MS/MS-based targeted metabolomic approach for the detection of amino acids and acylcarnitines in dried blood spots. GA affected the blood metabolome of premature neonates: male and female very premature infants (VPI) diverged in amino acids but not in acylcarnitines, whereas the opposite was observed in moderate or late preterm infants (MLPI). Moreover, an important reduction of metabolites was observed in female VPI fed with PN, suggesting that PN might not satisfy an infant’s nutritional needs. Caffeine showed the highest significant impact on metabolite levels of male MLPI. This study proves the presence of a sex-dependent metabolome in premature infants, which is affected by GA and pharmacological treatment (e.g., caffeine). Furthermore, it describes an integrated relationship among several features of physiology and health.

ACS Style

Marianna Caterino; Margherita Ruoppolo; Michele Costanzo; Lucia Albano; Daniela Crisci; Giovanni Sotgiu; Laura Saderi; Andrea Montella; Flavia Franconi; Ilaria Campesi. Sex Affects Human Premature Neonates’ Blood Metabolome According to Gestational Age, Parenteral Nutrition, and Caffeine Treatment. Metabolites 2021, 11, 158 .

AMA Style

Marianna Caterino, Margherita Ruoppolo, Michele Costanzo, Lucia Albano, Daniela Crisci, Giovanni Sotgiu, Laura Saderi, Andrea Montella, Flavia Franconi, Ilaria Campesi. Sex Affects Human Premature Neonates’ Blood Metabolome According to Gestational Age, Parenteral Nutrition, and Caffeine Treatment. Metabolites. 2021; 11 (3):158.

Chicago/Turabian Style

Marianna Caterino; Margherita Ruoppolo; Michele Costanzo; Lucia Albano; Daniela Crisci; Giovanni Sotgiu; Laura Saderi; Andrea Montella; Flavia Franconi; Ilaria Campesi. 2021. "Sex Affects Human Premature Neonates’ Blood Metabolome According to Gestational Age, Parenteral Nutrition, and Caffeine Treatment." Metabolites 11, no. 3: 158.

Review article
Published: 05 March 2021 in Respiratory Medicine
Reads 0
Downloads 0

Non-pharmacological interventions and tracing-testing strategy proved insufficient to reduce SARS-CoV-2 spreading worldwide. Several vaccines with different mechanisms of action are currently under development. This review describes the potential target antigens evaluated for SARS-CoV-2 vaccine in the context of both conventional and next-generation platforms. We reported experimental data from phase-3 trials with a focus on different definitions of efficacy as well as factors affecting real-life effectiveness of SARS-CoV-2 vaccination, including logistical issues associated to vaccine availability, delivery, and immunization strategies. On this background, new variants of SARS-CoV-2 are discussed. We also provided a critical view on vaccination in special populations at higher risk of infection or severe disease as elderly people, pregnant women and immunocompromised patients. A final paragraph addresses safety on the light of the unprecedented reduction of length of the vaccine development process and faster authorization.

ACS Style

Francesco Blasi; Andrea Gramegna; Giovanni Sotgiu; Laura Saderi; Antonio Voza; Stefano Aliberti; Francesco Amati. SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. Respiratory Medicine 2021, 180, 106355 -106355.

AMA Style

Francesco Blasi, Andrea Gramegna, Giovanni Sotgiu, Laura Saderi, Antonio Voza, Stefano Aliberti, Francesco Amati. SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. Respiratory Medicine. 2021; 180 ():106355-106355.

Chicago/Turabian Style

Francesco Blasi; Andrea Gramegna; Giovanni Sotgiu; Laura Saderi; Antonio Voza; Stefano Aliberti; Francesco Amati. 2021. "SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity." Respiratory Medicine 180, no. : 106355-106355.

Comment
Published: 11 January 2021 in The Lancet Respiratory Medicine
Reads 0
Downloads 0

A year after the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its related disease, COVID-19, in the Chinese province of Hubei, one of the most difficult-to-manage modern health-care crises has unfolded worldwide. WHO declared COVID-19 a pandemic in March, 2020, and the epidemiological severity has since been shown by the high incidence of infections, critical cases, and deaths from the disease and, indirectly, by tragic socioeconomic disruption.

ACS Style

Laure Wynants; Giovanni Sotgiu. Improving clinical management of COVID-19: the role of prediction models. The Lancet Respiratory Medicine 2021, 9, 320 -321.

AMA Style

Laure Wynants, Giovanni Sotgiu. Improving clinical management of COVID-19: the role of prediction models. The Lancet Respiratory Medicine. 2021; 9 (4):320-321.

Chicago/Turabian Style

Laure Wynants; Giovanni Sotgiu. 2021. "Improving clinical management of COVID-19: the role of prediction models." The Lancet Respiratory Medicine 9, no. 4: 320-321.

Review article
Published: 15 December 2020 in Current Research in Pharmacology and Drug Discovery
Reads 0
Downloads 0

Even if major improvements in therapeutic regimens and treatment outcomes have been progressively achieved, tuberculosis (TB) remains the leading cause of death from a single infectious microorganism. To improve TB treatment success as well as patients' quality of life, drug-drug-interactions (DDIs) need to be wisely managed. Comprehensive knowledge of anti-TB drugs, pharmacokinetics and pharmacodynamic (PK/PD) parameters, potential patients’ changes in absorption and distribution, possible side effects and interactions, is mandatory to built effective anti-TB regimens. Optimization of treatments and adherence to international guidelines can help bend the curve of TB-related mortality and, ultimately, decrease the likelihood of treatment failure and drop-out during anti-TB treatment. Aim of this paper is to describe the most relevant DDIs between anti-TB and other drugs used in daily clinical practice, providing an updated and “easy-to-use” guide to minimize adverse effects, drop-outs and, in the long run, increase treatment success.

ACS Style

Niccolò Riccardi; Diana Canetti; Paola Rodari; Giorgio Besozzi; Laura Saderi; Marco Dettori; Luigi R. Codecasa; Giovanni Sotgiu. Tuberculosis and pharmacological interactions: A narrative review. Current Research in Pharmacology and Drug Discovery 2020, 2, 100007 .

AMA Style

Niccolò Riccardi, Diana Canetti, Paola Rodari, Giorgio Besozzi, Laura Saderi, Marco Dettori, Luigi R. Codecasa, Giovanni Sotgiu. Tuberculosis and pharmacological interactions: A narrative review. Current Research in Pharmacology and Drug Discovery. 2020; 2 ():100007.

Chicago/Turabian Style

Niccolò Riccardi; Diana Canetti; Paola Rodari; Giorgio Besozzi; Laura Saderi; Marco Dettori; Luigi R. Codecasa; Giovanni Sotgiu. 2020. "Tuberculosis and pharmacological interactions: A narrative review." Current Research in Pharmacology and Drug Discovery 2, no. : 100007.

Review
Published: 01 December 2020 in Infection and Drug Resistance
Reads 0
Downloads 0

Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-β-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.

ACS Style

Daniele Roberto Giacobbe; Eugenio Ciacco; Corrado Girmenia; Federico Pea; Gian Maria Rossolini; Giovanni Sotgiu; Carlo Tascini; Mario Tumbarello; Pierluigi Viale; Matteo Bassetti. Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Infection and Drug Resistance 2020, ume 13, 4697 -4711.

AMA Style

Daniele Roberto Giacobbe, Eugenio Ciacco, Corrado Girmenia, Federico Pea, Gian Maria Rossolini, Giovanni Sotgiu, Carlo Tascini, Mario Tumbarello, Pierluigi Viale, Matteo Bassetti. Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Infection and Drug Resistance. 2020; ume 13 ():4697-4711.

Chicago/Turabian Style

Daniele Roberto Giacobbe; Eugenio Ciacco; Corrado Girmenia; Federico Pea; Gian Maria Rossolini; Giovanni Sotgiu; Carlo Tascini; Mario Tumbarello; Pierluigi Viale; Matteo Bassetti. 2020. "Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data." Infection and Drug Resistance ume 13, no. : 4697-4711.

Brief definitive report
Published: 23 November 2020 in Liver International
Reads 0
Downloads 0

Inmates have higher HCV prevalence than general population, representing a fundamental step towards HCV eradication. Our aim was to compare eight‐weeks glecaprevir/pibrentasvir treatment in a case‐control study between incarcerated and free patients. Eleven Italian prisons and six outpatient clinics were involved. Patients were matched for sex, risk factors, METAVIR grade, HIV and HBV co‐infections. 131 incarcerated (Group A) and 131 free patients (Group B) were included. Mean age was 43.0±9.6 years and 42.8±9.9 in Group A and B, respectively (p=0.74). SVR rates were 96.2% and 99.2% in Group A and Group B respectively (p=0.21). Five drop‐outs occurred in Group A, one in Group B. Incarceration, being PWIDs and OST were not associated to SVR reductions (CI 95%). In conclusion, imprisonment does not influence unplanned interruptions or SVR rates when receiving short‐term therapies. Short schedules with pangenotypic regimens could be a good approach to hard‐to‐reach populations, such as incarcerated patients.

ACS Style

Vito Fiore; Roberto Ranieri; Serena Dell’Isola; Emanuele Pontali; Giorgio Barbarini; Tullio Prestileo; Daniele Marri; Giulio Starnini; Giovanni Sotgiu; Giordano Madeddu; Sergio Babudieri; SIMSPe Group. Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case‐control study. Liver International 2020, 41, 271 -275.

AMA Style

Vito Fiore, Roberto Ranieri, Serena Dell’Isola, Emanuele Pontali, Giorgio Barbarini, Tullio Prestileo, Daniele Marri, Giulio Starnini, Giovanni Sotgiu, Giordano Madeddu, Sergio Babudieri, SIMSPe Group. Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case‐control study. Liver International. 2020; 41 (2):271-275.

Chicago/Turabian Style

Vito Fiore; Roberto Ranieri; Serena Dell’Isola; Emanuele Pontali; Giorgio Barbarini; Tullio Prestileo; Daniele Marri; Giulio Starnini; Giovanni Sotgiu; Giordano Madeddu; Sergio Babudieri; SIMSPe Group. 2020. "Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case‐control study." Liver International 41, no. 2: 271-275.

Short report
Published: 22 October 2020 in Virology Journal
Reads 0
Downloads 0

Background Human Papillomavirus (HPV) infection is one of the most important causes of cancer. It can play a role in cervical and extra-cervical cancers. Penile cancer is rare, even if an increasing trend was recently reported. Aim of the present study was to assess the prevalence and distribution of HPV genotypes in cases of penile cancer diagnosed in Sardinia, Italy. Surrogate markers of HPV infection (i.e., E6 and p16 genes) were also evaluated in all cases. Methods An observational, retrospective study which recruited all cases of penile cancer diagnosed between 2002 and 2019 at a tertiary care hospital in Sardinia, Italy, was carried out. HPV-DNA detection and genotyping were performed by Real-time PCR. Specimens were tested for oncogene E6 mRNA and for p16(INK4a) expression. Results HPV prevalence was 28.1% (9/32); HPV-16 was the most prevalent genotype (7/9, 77.8%). p16INK4a positivity was found in 66.7% of the samples with a statistically significant difference between HPV-positive and -negative groups. E6-transcript was detected in 71% of the HPV-16 positive samples. The overall survival was not statistically different between HPV-positives and -negatives. Discussion The present study confirms the etiologic role of HPV in penile cancer and supports the adoption of vaccination strategies in men and women. Further studies should clarify the diagnostic and prognostic role of E6 and p16 proteins. Conclusion HPV infection can favor the occurrence of penile cancer, whose diagnosis and prognosis could be improved with the implementation of validated molecular techniques.

ACS Style

Narcisa Muresu; Giovanni Sotgiu; Laura Saderi; Illari Sechi; Antonio Cossu; Vincenzo Marras; Marta Meloni; Marianna Martinelli; Clementina Cocuzza; Francesco Tanda; Andrea Piana. Italian observational study on HPV infection, E6, and p16 expression in men with penile cancer. Virology Journal 2020, 17, 1 -6.

AMA Style

Narcisa Muresu, Giovanni Sotgiu, Laura Saderi, Illari Sechi, Antonio Cossu, Vincenzo Marras, Marta Meloni, Marianna Martinelli, Clementina Cocuzza, Francesco Tanda, Andrea Piana. Italian observational study on HPV infection, E6, and p16 expression in men with penile cancer. Virology Journal. 2020; 17 (1):1-6.

Chicago/Turabian Style

Narcisa Muresu; Giovanni Sotgiu; Laura Saderi; Illari Sechi; Antonio Cossu; Vincenzo Marras; Marta Meloni; Marianna Martinelli; Clementina Cocuzza; Francesco Tanda; Andrea Piana. 2020. "Italian observational study on HPV infection, E6, and p16 expression in men with penile cancer." Virology Journal 17, no. 1: 1-6.

Journal article
Published: 19 October 2020 in Nature Medicine
Reads 0
Downloads 0

The risk of tuberculosis (TB) is variable among individuals with latent Mycobacterium tuberculosis infection (LTBI), but validated estimates of personalized risk are lacking. In pooled data from 18 systematically identified cohort studies from 20 countries, including 80,468 individuals tested for LTBI, 5-year cumulative incident TB risk among people with untreated LTBI was 15.6% (95% confidence interval (CI), 8.0–29.2%) among child contacts, 4.8% (95% CI, 3.0–7.7%) among adult contacts, 5.0% (95% CI, 1.6–14.5%) among migrants and 4.8% (95% CI, 1.5–14.3%) among immunocompromised groups. We confirmed highly variable estimates within risk groups, necessitating an individualized approach to risk stratification. Therefore, we developed a personalized risk predictor for incident TB (PERISKOPE-TB) that combines a quantitative measure of T cell sensitization and clinical covariates. Internal–external cross-validation of the model demonstrated a random effects meta-analysis C-statistic of 0.88 (95% CI, 0.82–0.93) for incident TB. In decision curve analysis, the model demonstrated clinical utility for targeting preventative treatment, compared to treating all, or no, people with LTBI. We challenge the current crude approach to TB risk estimation among people with LTBI in favor of our evidence-based and patient-centered method, in settings aiming for pre-elimination worldwide. The risk of developing active tuberculosis (TB) in individuals with latent TB infection is highly variable within and among different risk groups. A personalized risk predictor was developed to better target preventative treatment to individuals at greatest risk, supporting evidence-based clinical decision-making for latent TB.

ACS Style

Rishi K. Gupta; Claire J. Calderwood; Alexei Yavlinsky; Maria Krutikov; Matteo Quartagno; Maximilian C. Aichelburg; Neus Altet; Roland Diel; Claudia C. Dobler; Jose Dominguez; Joseph S. Doyle; Connie Erkens; Steffen Geis; Pranabashis Haldar; Anja M. Hauri; Thomas Hermansen; James C. Johnston; Christoph Lange; Berit Lange; Frank van Leth; Laura Muñoz; Christine Roder; Kamila Romanowski; David Roth; Martina Sester; Rosa Sloot; Giovanni Sotgiu; Gerrit Woltmann; Takashi Yoshiyama; Jean-Pierre Zellweger; Dominik Zenner; Robert W. Aldridge; Andrew Copas; Molebogeng X. Rangaka; Marc Lipman; Mahdad Noursadeghi; Ibrahim Abubakar. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nature Medicine 2020, 26, 1941 -1949.

AMA Style

Rishi K. Gupta, Claire J. Calderwood, Alexei Yavlinsky, Maria Krutikov, Matteo Quartagno, Maximilian C. Aichelburg, Neus Altet, Roland Diel, Claudia C. Dobler, Jose Dominguez, Joseph S. Doyle, Connie Erkens, Steffen Geis, Pranabashis Haldar, Anja M. Hauri, Thomas Hermansen, James C. Johnston, Christoph Lange, Berit Lange, Frank van Leth, Laura Muñoz, Christine Roder, Kamila Romanowski, David Roth, Martina Sester, Rosa Sloot, Giovanni Sotgiu, Gerrit Woltmann, Takashi Yoshiyama, Jean-Pierre Zellweger, Dominik Zenner, Robert W. Aldridge, Andrew Copas, Molebogeng X. Rangaka, Marc Lipman, Mahdad Noursadeghi, Ibrahim Abubakar. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nature Medicine. 2020; 26 (12):1941-1949.

Chicago/Turabian Style

Rishi K. Gupta; Claire J. Calderwood; Alexei Yavlinsky; Maria Krutikov; Matteo Quartagno; Maximilian C. Aichelburg; Neus Altet; Roland Diel; Claudia C. Dobler; Jose Dominguez; Joseph S. Doyle; Connie Erkens; Steffen Geis; Pranabashis Haldar; Anja M. Hauri; Thomas Hermansen; James C. Johnston; Christoph Lange; Berit Lange; Frank van Leth; Laura Muñoz; Christine Roder; Kamila Romanowski; David Roth; Martina Sester; Rosa Sloot; Giovanni Sotgiu; Gerrit Woltmann; Takashi Yoshiyama; Jean-Pierre Zellweger; Dominik Zenner; Robert W. Aldridge; Andrew Copas; Molebogeng X. Rangaka; Marc Lipman; Mahdad Noursadeghi; Ibrahim Abubakar. 2020. "Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings." Nature Medicine 26, no. 12: 1941-1949.